The Oncology Institute, Inc. (TOI) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

The Oncology Institute, Inc. (TOI) Healthcare & Pipeline Overview

The Oncology Institute, Inc. (TOI) delivers integrated oncology care through a network of clinics, offering services from physician consultations to clinical trials. With a focus on adult and senior cancer patients, TOI operates in the fragmented U.S. medical care facilities market, balancing growth with profitability amid competitive pressures.

What Is the Investment Thesis for TOI?

The Oncology Institute, Inc. presents an investment opportunity within the growing oncology care market. Key value drivers include the expansion of its clinic network, increased patient volume, and the continued development of its integrated service model. While TOI's gross margin stands at 13.5%, profitability remains a challenge with a negative profit margin of -8.0%. Growth catalysts include the aging U.S. population and advancements in cancer treatment modalities. The company's low beta of 0.20 suggests lower volatility compared to the broader market. However, investors should be aware of risks associated with reimbursement rates, regulatory changes, and competition within the medical care facilities sector. The company's ability to achieve economies of scale and improve operational efficiency will be critical to achieving sustainable profitability.

Based on FMP financials and quantitative analysis

TOI Key Highlights

Operates 67 clinic locations across the United States, providing a broad geographic footprint for patient access.

• Offers a comprehensive suite of oncology services, including physician services, in-house infusion and dispensary, clinical trial services, radiation, outpatient stem cell transplants and transfusions programs, and patient support.
• Focuses on adult and senior cancer patients, addressing a significant and growing demographic in the U.S.
• Gross margin of 13.5% indicates potential for improved profitability through operational efficiencies.
• Beta of 0.20 suggests lower volatility compared to the broader market, potentially offering a more stable investment profile.

Who Are TOI's Competitors?

TOI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are TOI's Key Strengths?

Integrated service model.

• Established clinic network.
• Clinical trial expertise.
• Focus on adult and senior cancer patients.

What Are TOI's Weaknesses?

Negative profit margin.

• Reliance on reimbursement rates.
• Competition from larger healthcare providers.
• Potential for regulatory changes.

What Could Drive TOI Stock Higher?

Expansion of clinic network to new geographic areas.

• Increased patient volume through marketing and outreach efforts.
• Potential partnerships with pharmaceutical companies for clinical trials.
• Development and implementation of new cancer treatment modalities.

What Are the Key Risks for TOI?

Changes in reimbursement rates from insurance companies and government payers.

• Increased competition from larger healthcare providers and other oncology centers.
• Rising cost of cancer treatments and medications.
• Economic downturn impacting patient access to care.
• Regulatory changes affecting the healthcare industry.

What Are the Growth Opportunities for TOI?

• Expansion of Clinic Network: The Oncology Institute, Inc. has the opportunity to expand its geographic footprint by opening new clinic locations in underserved markets. This expansion would allow TOI to reach a larger patient population and increase its revenue base. The market for oncology services is expected to grow as the population ages, creating a favorable environment for expansion. The timeline for expansion would depend on factors such as capital availability, regulatory approvals, and market demand. A successful expansion strategy could significantly increase TOI's market share and profitability.
• Increased Patient Volume: TOI can increase patient volume at its existing clinics by enhancing its marketing efforts and building stronger relationships with referring physicians. By attracting more patients to its clinics, TOI can increase its revenue and improve its operational efficiency. The market for oncology services is highly competitive, so TOI must differentiate itself by providing high-quality care and a positive patient experience. A successful patient acquisition strategy could significantly boost TOI's revenue and profitability.
• Development of Integrated Service Model: TOI's integrated service model, which offers a comprehensive range of oncology services under one roof, provides a competitive advantage. By continuing to develop and refine this model, TOI can improve patient outcomes, enhance the patient experience, and reduce costs. The market for integrated oncology services is growing as patients and payers increasingly seek value-based care. A successful integrated service model could position TOI as a leader in the oncology care market.
• Strategic Partnerships and Acquisitions: The Oncology Institute, Inc. can pursue strategic partnerships and acquisitions to expand its service offerings and geographic reach. By partnering with other healthcare providers, TOI can offer a wider range of services to its patients and reach new markets. Acquisitions can also provide TOI with access to new technologies, expertise, and patient populations. The market for healthcare partnerships and acquisitions is active, so TOI must carefully evaluate potential opportunities to ensure they align with its strategic goals.
• Clinical Trial Expansion: TOI can further expand its clinical trial services, attracting more patients and generating additional revenue. By offering a wider range of clinical trials, TOI can provide its patients with access to cutting-edge treatments and contribute to the advancement of cancer research. The market for clinical trials is growing as pharmaceutical companies increasingly rely on community-based oncology practices to conduct their research. A successful clinical trial expansion strategy could significantly enhance TOI's reputation and profitability.

What Are TOI's Competitive Advantages?

• Integrated service model: Offers a comprehensive range of oncology services under one roof, providing a convenient and coordinated patient experience.
• Established clinic network: Operates 67 clinic locations, providing a broad geographic footprint for patient access.
• Clinical trial expertise: Manages and conducts clinical trials, providing access to cutting-edge treatments and generating additional revenue.
• Focus on adult and senior cancer patients: Addresses a significant and growing demographic in the U.S.

What Does TOI Do?

Founded in 2007 and headquartered in Cerritos, California, The Oncology Institute, Inc. (TOI) is a comprehensive oncology provider dedicated to serving adult and senior cancer patients in the United States. TOI operates an integrated model with 67 clinic locations, offering a range of services including physician consultations, in-house infusion and dispensary, clinical trial management, radiation therapy, outpatient stem cell transplants, transfusions, and patient support programs. This integrated approach allows TOI to manage patient care from diagnosis through treatment, ensuring a coordinated and patient-centric experience. The company manages clinical trials, palliative care programs, and stem cell transplant services. TOI's focus on providing comprehensive care under one roof differentiates it from more fragmented oncology service providers. By offering a full suite of services, TOI aims to improve patient outcomes and enhance the overall patient experience. The company's growth strategy involves expanding its clinic network and service offerings to reach more patients in need of specialized cancer care.

What Products and Services Does TOI Offer?

• Provides physician services for cancer patients.
• Offers in-house infusion and dispensary services.
• Manages and conducts clinical trial services.
• Provides radiation therapy.
• Offers outpatient stem cell transplants and transfusions programs.
• Provides patient support services.
• Manages palliative care programs.

How Does TOI Make Money?

• Generates revenue through providing medical oncology services to adult and senior cancer patients.
• Receives payments from insurance companies and government payers for services rendered.
• Manages clinical trials, generating revenue from pharmaceutical companies and research organizations.
• Operates an integrated model with 67 clinic locations, providing a comprehensive range of services under one roof.

What Industry Does TOI Operate In?

The Oncology Institute, Inc. operates within the medical care facilities industry, which is characterized by increasing demand for specialized cancer care services. The aging U.S. population and rising cancer incidence rates are driving market growth. The industry is competitive, with a mix of large hospital systems, specialized oncology centers, and smaller independent practices. TOI's integrated model aims to differentiate it from competitors by offering a comprehensive range of services under one roof. The industry faces ongoing challenges related to reimbursement rates, regulatory changes, and the increasing cost of cancer treatments.

Who Are TOI's Key Customers?

• Adult cancer patients.
• Senior cancer patients.
• Insurance companies.
• Government payers (e.g., Medicare, Medicaid).

Company Profile

The Oncology Institute, Inc. operates in the Medical - Care Facilities industry within the Healthcare sector. It is headquartered in Cerritos, US. The company is led by CEO Daniel Virnich. TOI has traded publicly since 2020.

The Oncology Institute, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 2.34 places it in the grey zone, a middle ground that warrants monitoring.

Return on equity for The Oncology Institute, Inc. stands at 209.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -20.4%, showing how much profit it generates from its asset base. Its free cash flow yield is -0.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.36 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -0.7%, the inverse of the P/E and a quick read on earnings relative to price.

TOI Valuation & Market Position

With a $513M market cap, The Oncology Institute, Inc. sits in the small-cap segment of the market.

Wall Street analysts project The Oncology Institute, Inc. revenue of about $651.8M for fiscal 2026, with EPS near $-0.14. The estimate reflects 3 contributing analysts.

TOI Financials

TOI Latest News

Common Questions About TOI (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources